Advertisement

A Behavioral Adherence Intervention Improves Rates of Viral Suppression Among Adherence-Challenged People Living with HIV in South India

  • Maria L. EkstrandEmail author
  • Elsa Heylen
  • Matilda Pereira
  • Jacob D’Souza
  • Shoba Nair
  • Amanda Mazur
  • Ranjani Shamsundar
  • B. N. Ravi Kumar
  • Sara Chandy
Original Paper

Abstract

The success of antiretroviral therapy (ART) has led to both extended life expectancy and improved quality of life among people living with HIV (PLWH). To maximize the efficacy of first line ART regimens in low- and middle-income countries (LMIC), we need culturally-relevant interventions that empower participants to reduce barriers to long-term uninterrupted adherence. The Chetana adherence intervention trial was designed in collaboration with local community groups as a comprehensive wellness program for adherence-challenged PLWH and included peer-led adherence support, yoga, nutrition, information about local resources, and individual counseling using motivational interviewing techniques. Intervention arm participants were almost twice as likely to be virally suppressed at their 12-month follow-up visit (AOR = 1.98; 95% CI [1.2, 3.23]) as were participants in the active control arm. They were also about twice as likely as control arm participants to self-report ≥ 95% adherence (AOR = 1.86, 95% CI [1.09, 3.15]), and as having eliminated individual adherence barriers (AOR = 2.33, 95% CI [1.51, 3.62]) and clinic attendance barriers (AOR = 2.01, 95% CI [1.20, 3.38]) These low-cost strategies can be implemented by local NGOs, making it both scalable and sustainable in this and similar settings.

Keywords

HIV ART adherence trial Viral suppression India PLWH LMIC Cultural relevance 

Notes

Acknowledgements

We gratefully acknowledge the staff at the Karnataka ART Centres for referring the study participants as well as the Chetana study staff for their hard work and dedication to the study participants. Finally, we are grateful to the many study participants who so generously shared their time and thoughts with us.

Author Contributions

ME and SC conceived of and designed the study. The first draft of the manuscript was written by ME and EH. All authors commented on previous versions of the manuscript, read and approved the final manuscript.

Funding

This study was funded by the National Institutes of Health (R01MH095659).

Compliance with Ethical Standards

Conflict of interest

The authors declare they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standard of the Ethics Committees of the University of California, San Francisco and St. John’s Research Institute and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science (New York, NY). 2013;339(6122):961–5.CrossRefGoogle Scholar
  3. 3.
    UNAIDS. UNAIDS Data 2018. Geneva, Switzerland; 2018.Google Scholar
  4. 4.
    Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a Cohort Study. Ann Intern Med. 2018;169(6):376–84.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Ekstrand ML, Chandy S, Heylen E, Steward W, Singh G. Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study. J Acquir Immun Defic Syndr. 2010;53(3):415–6.CrossRefGoogle Scholar
  6. 6.
    Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515–21.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44–51.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retrovir. 2004;20(10):1053–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS ONE ONE. 2010;5(10):e13414.CrossRefGoogle Scholar
  11. 11.
    Reda AA, Biadgilign S. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Res Treat. 2012;2012:574656.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17:1785–95.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdottir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Steward WT, Bharat S, Ramakrishna J, Heylen E, Ekstrand ML. Stigma is associated with delays in seeking care among HIV-infected people in India. J Int Assoc Provid AIDS Care. 2013;12(2):103–9.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Byakika-Tusiime J, Crane J, Oyugi JH, Ragland K, Kawuma A, Musoke P, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(Suppl 1):82–91.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kong MC, Nahata MC, Lacombe VA, Seiber EE, Balkrishnan R. Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection. J Gen Intern Med. 2012;27(9):1159–64.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Nakashima AK. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS ONE ONE. 2007;2(6):e552.CrossRefGoogle Scholar
  18. 18.
    Orrell C, Cohen K, Mauff K, Maartens G, Wood R, DR. B. Randomised controlled trial of text-message dosing reminders in patients starting ART. 22nd Conference on Retroviruses and Opportunistic Infections (CROI), Abstract 559. Seattle, WA, February 23–26, 2015.Google Scholar
  19. 19.
    Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS ONE ONE. 2010;5(4):e10340.CrossRefGoogle Scholar
  20. 20.
    Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014;11(3):291–307.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, et al. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS ONE ONE. 2014;9(8):e104178.CrossRefGoogle Scholar
  23. 23.
    Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.PubMedCrossRefGoogle Scholar
  24. 24.
    Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2012;25:400–14.Google Scholar
  25. 25.
    Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3(1):27–34.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Vallabhaneni S, Chandy S, Heylen E, Ekstrand M. Reasons for and correlates of antiretroviral treatment interruptions in a cohort of patients from public and private clinics in southern India. AIDS Care. 2012;24(6):687–94.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Batavia AS, Balaji K, Houle E, Parisaboina S, Ganesh AK, Mayer KH, et al. Adherence to antiretroviral therapy in patients participating in a graduated cost recovery program at an HIV care center in South India. AIDS Behav. 2010;14(4):794–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDs. 2010;24:795–803.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Kleinman NJ, Manhart LE, Mohanraj R, Kumar S, Jeyaseelan L, Rao D, et al. Antiretroviral therapy adherence measurement in non-clinical settings in South India. AIDS Care. 2015;27(2):248–54.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Joshi B, Chauhan S, Pasi A, Kulkarni R, Sunil N, Bachani D, et al. Level of suboptimal adherence to first line antiretroviral treatment & its determinants among HIV positive people in India. Indian J Med Res. 2014;140(1):84–95.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Hamide A, Shamanna SB, Balaguru S, Subbian M. Long-term outcome of HIV-infected patients treated at a tertiary care hospital in southern India. Natl Med J India. 2014;27(3):134–7.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45(3):334–41.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. India. AIDS Res Ther. 2009;6:7.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Meena LP, Pandey SK, Rai M, Bharti A, Chakravarty J, Sundar S. Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. J Educ Health Promot. 2014;3:31.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Ekstrand ML, Bharat S, Srinivasan K. HIV stigma is a barrier to achieving 90-90-90 in India. Lancet HIV. 2018;5(10):e543–e545545.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Steward WT, Herek GM, Ramakrishna J, Bharat S, Chandy S, Wrubel J, et al. HIV-related stigma: adapting a theoretical framework for use in India. Soc Sci Med. 2008;67(8):1225–35.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Steward WT, Chandy S, Singh G, Panicker ST, Osmand TA, Heylen E, et al. Depression is not an inevitable outcome of disclosure avoidance: HIV stigma and mental health in a cohort of HIV-infected individuals from Southern India. Psychol Health Med. 2011;16(1):74–85.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kanters S, Park JJ, Chan K, Socias ME, Ford N, Forrest JI, et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV. 2017;4(1):e31–e40.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    de Bruin M, Oberjé EJ, Viechtbauer W, Nobel H-E, Hiligsmann M, van Nieuwkoop C, et al. Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial. Lancet Infect Dis. 2017;17(6):595–604.PubMedCrossRefGoogle Scholar
  41. 41.
    Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to improve adherence to antiretroviral medication. AIDS (London, England). 2017;31(5):719.CrossRefGoogle Scholar
  42. 42.
    McCoy SI, Njau PF, Fahey C, Kapologwe N, Kadiyala S, Jewell NP, et al. Cash versus food assistance to improve adherence to antiretroviral therapy among HIV-infected adults in Tanzania: a randomized trial. AIDS (London, England). 2017;31(6):815.CrossRefGoogle Scholar
  43. 43.
    Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and acceptability of a task-shifted intervention to enhance adherence to HIV medication and improve depression in people living with HIV in Zimbabwe, a low income country in Sub-Saharan Africa. AIDS Behav. 2018;22(1):86–101.PubMedCrossRefGoogle Scholar
  44. 44.
    Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al. Cultural adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. J Health Psychol. 2017;22(10):1265–76.PubMedCrossRefGoogle Scholar
  45. 45.
    National Aids Control Organization (NACO) MoHaFW, Governemnt of India; National Strategic Plan for HIV/AIDS and STI 2017–2014. New Delhi, India: NACO; 2017.Google Scholar
  46. 46.
    Bandura A. Health promotion by social cognitive means. Health Educ Behav. 2004;31(2):143–64.PubMedCrossRefGoogle Scholar
  47. 47.
    Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–40.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41(10):4531–6.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med. 2006;25(24):4216–26.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of Medicine, Center for AIDS Prevention StudiesUniversity of CaliforniaSan FranciscoUSA
  2. 2.St John’s Research Institute, St John’s National Academy of Health SciencesBangaloreIndia
  3. 3.St John’s Medical College and Hospital, St John’s National Academy of Health SciencesBangaloreIndia
  4. 4.Karnataka State AIDS Prevention SocietyBangaloreIndia

Personalised recommendations